ライフサイエンスコーパス: secondary prevention

1 to prevent new episodes of thrombosis ("pure secondary prevention").

2 older adults with already impaired function (secondary prevention).

3 placebo-controlled trial of pioglitazone for secondary prevention.

4 without comorbidities on statin therapy for secondary prevention.

5 festyle programs with regular hospital-based secondary prevention.

6 ent of HE, while seven looked at its primary/secondary prevention.

7 reduction was comparable to that achieved in secondary prevention.

8 nt the implementation of optimal primary and secondary prevention.

9 from 12 trials of aspirin versus control in secondary prevention.

10 on of and nonadherence to statin therapy for secondary prevention.

11 solidified the historical role of aspirin in secondary prevention.

12 ning is common, providing an opportunity for secondary prevention.

13 potential implications in CRC screening and secondary prevention.

14 e the treatments used in acute stroke and in secondary prevention.

15 ure combinations could facilitate its use in secondary prevention.

16 e (ie, cryptogenic), potentially undermining secondary prevention.

17 t rupture risk might be reduced by intensive secondary prevention.

18 ocardial infarction (MI) is a cornerstone of secondary prevention.

19 ion and obesity may be important targets for secondary prevention.

20 icillin injections remain the cornerstone of secondary prevention.

21 anticoagulation vs antiplatelet therapy for secondary prevention.

22 novel intensive lipid-lowering therapies for secondary prevention.

23 ed from 40 centers, including 104 (63.0%) in secondary prevention.

24 of sleep, with implications for primary and secondary prevention.

25 ediction and identify novel drug targets for secondary prevention.

26 , a group who requires long-term therapy for secondary prevention.

27 s the potential to guide medical therapy for secondary prevention.

28 ome (LMICs) use guideline-directed drugs for secondary prevention.

29 sis In Myocardial Infarction) Risk Score for Secondary Prevention.

30 tudies (n): 0.50/0.40-0.64/0%/6] and primary/secondary prevention (0.66/0.57-0.76/57%/18).

31 III trial, 477 received a defibrillator for secondary prevention; 248 patients were randomly assigne

32 o determine the association between baseline secondary prevention achievement and cardiovascular deat

33 between individual and regional factors and secondary prevention achievement at baseline.

34 addition of ezetimibe to statin therapy for secondary prevention after ACS.

35 appropriate adherence to CV medications for secondary prevention after an acute MI.

36 implantation of newer-generation DES and in secondary prevention after MI.

37 peutic decision making for vorapaxar use for secondary prevention after MI.

38 as a risk factor requiring intervention for secondary prevention after percutaneous coronary revascu

39 ndomised trials of aspirin versus control in secondary prevention after TIA or ischaemic stroke, we s

40 Aspirin is recommended for secondary prevention after transient ischaemic attack (T

41 primary treatment (first 3 to 6 months), and secondary prevention (after the initial 3 to 6 months).

42 will be difficult to deploy, strategies for secondary prevention aimed at later stages of disease ar

43 sis in Myocardial Infarction) Risk Score for Secondary Prevention, all patients with DM demonstrated

44 have assessed the role of supplementation in secondary prevention among patients with diabetes mellit

45 efibrillators, all de novo implantations for secondary prevention and all implantations and appropria

46 rence by 33% compared with usual care in CVD secondary prevention and has been recommended as a "best

47 ases because of its well-established role in secondary prevention and its widespread availability and

48 Guideline-directed medications for secondary prevention and risk factor control are recomme

49 mass index (BMI) with use of medications for secondary prevention and risk factor control in patients

50 In the article by Smith et al, "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Pati

51 Antithrombotic medications are paramount for secondary prevention and thus crucial to reduce the over

52 assessed in cardiovascular disease patients (secondary prevention) and for two blood pressure ranges

53 ith pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolu

54 ional tests for risk prediction, primary and secondary prevention, and laboratory testing.

55 ional insurance to cover primary prevention, secondary prevention, and tertiary treatment for cardiov

56 tegies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction

57 Trials of secondary prevention are urgently required to determine

58 Although strategies for primary and secondary prevention are well established, their worldwi

59 and across subgroups by TIMI Risk Score for Secondary Prevention at baseline ( P>0.05 for randomized

60 scents, and children and maintain and target secondary prevention at the population older than 60 yea

61 fine the traditional paradigm of primary and secondary prevention based on population-derived risk es

62 ditional differentiation between primary and secondary prevention based simply on clinical history.

63 te ischemic stroke are in need of hyperacute secondary prevention because the risk of recurrence is h

64 This suggests that secondary prevention before onset, when beta-cell mass i

65 (RESPONSE-2: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists 2;

66 r care, mobility assessments, and consistent secondary prevention can prove to be key elements to imp

67 The prevalence of the use of secondary prevention cardiovascular medications is lower

68 ist to improve the quality of cardiovascular secondary prevention care among patients with diabetes m

69 h primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with st

70 mortality, 1.09; 95% CI, 1.08-1.10) and the secondary prevention cohort (aHR for stroke, 1.11; 95% C

71 with no prior cardiovascular event, and the secondary prevention cohort comprised individuals >/=30

72 of UGIB was lower in the primary than in the secondary prevention cohort, numbers needed to harm per

73 In the secondary prevention cohort, the prevalence and treatmen

74 <=10 000 and within each of the primary and secondary prevention cohorts, compared cardiovascular ri

75 nhanced benefit with clopidogrel therapy for secondary prevention compared with aspirin.

76 scular disease, adoption of the polypill for secondary prevention compared with current care was proj

77 strategies for studying diseases subject to secondary prevention, comparing the following: 1) CRC ca

78 r whom the goal of antithrombotic therapy is secondary prevention, concomitant coronary artery diseas

79 We modelled baseline use of secondary prevention drugs on the Prospective Urban Rura

80 polypill at current rates of prescription of secondary prevention drugs would produce modest health b

81 Primary and secondary prevention efforts targeted at sexual minority

82 roke patients treated with acenocoumarol for secondary prevention enrolled as part of the prospective

83 For secondary prevention following acute MI, younger age, de

84 f the universal need for lifelong aspirin in secondary prevention for all adults with CCS, particular

85 Primary prevention exceeds secondary prevention for CHD and pediatrics.

86 VD, including tobacco use, hypertension, and secondary prevention for CVD, will lead to the biggest g

87 mphasize the need to provide more aggressive secondary prevention for patients who experience type 2

88 imary end point event rate was higher in the secondary prevention group compared with the primary pre

89 the treatment effect across the primary and secondary prevention groups.

90 ICDs placed for secondary prevention have higher rates of appropriate th

91 Populations include secondary prevention, high-risk primary prevention based

92 he primary (HR, 0.98; 95% CI, 0.74-1.30) and secondary prevention (HR, 0.82; 95% CI, 0.72-0.95) cohor

93 Registry ICD Registry undergoing first-time secondary prevention ICD implantation between 2006 and 2

94 Almost 1 in 5 older patients receiving a secondary prevention ICD survives at least 2 years.

95 iomyopathy index cases, 44 patients received secondary prevention implantable cardioverter-defibrilla

96 An ICD was implanted for secondary prevention in 10 patients (9.6%) and for prima

97 were primary prevention in 1943 (61.9%) and secondary prevention in 1107 (35.2%).

98 in receptor blocker (ARB) should be used for secondary prevention in all or in only high-risk patient

99 ls comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis and aspirin

100 rtality of older patients receiving ICDs for secondary prevention in contemporary clinical practice.

101 w-dose aspirin may have a continuing role in secondary prevention in HF and underline the need for mo

102 efforts to target early Abeta deposition for secondary prevention in individuals with autosomal domin

103 es of bleeding on antiplatelet treatment for secondary prevention in patients of all ages.

104 cetylsalicylic acid is of proven benefit for secondary prevention in patients with cardiovascular dis

105 herapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established athero

106 mend additional lipid-lowering therapies for secondary prevention in patients with low-density lipopr

107 hough statin medications are recommended for secondary prevention in peripheral arterial disease, the

108 igh risk inherited arrhythmic conditions and secondary prevention in survivors of sudden cardiac arre

109 527 users of low-dose aspirin for primary or secondary prevention in the Swedish prescription registe

110 y treatments are worthy of consideration for secondary prevention in these patients if ongoing trials

111 Efforts to improve secondary prevention in this population should be focuse

112 Little evidence exists to guide secondary prevention in this population.

113 Unintended consequences of secondary prevention include potential introduction of b

114 exist, despite current standards of care for secondary prevention, including lifestyle changes, optim

115 lthough eliminating patient cost sharing for secondary prevention increases adherence and reduces rat

116 acceptability are low for medicines used in secondary prevention; increasing use is positively relat

117 sease (2 points); renal dialysis (3 points); secondary prevention indication (1 point); and ICD type:

118 dence interval: 1.87 to 13.14; p < 0.01) and secondary prevention indication (hazard ratio: 6.85; 95%

119 S) mean profile (3.9 vs 3.3, p = 0.01), more secondary prevention indication for a defibrillator (64.

120 fferences were consistent across primary and secondary prevention indications for statin treatment.

121 ng the importance of longitudinal, sustained secondary prevention initiatives.

122 Optimal secondary prevention is critical for the reduction of re

123 d be taken into account when the duration of secondary prevention is determined.

124 This therapy, which is sometimes labeled as secondary prevention, is effective in preventing recurre

125 ional tests for risk prediction, primary and secondary prevention, laboratory testing, physical activ

126 ly met very high-risk criteria for intensive secondary prevention lipid-lowering therapy (28.3% vs. 4

127 scular risk according to TIMI Risk Score for Secondary Prevention (<=2, 3, 4, and >=5 points, respect

128 Aspirin as secondary prevention may be more justified from a risk-b

129 Primary and secondary prevention measures are important for controll

130 Thus, secondary prevention measures are recommended for these

131 aphylaxis Registry were analyzed to identify secondary prevention measures offered to patients who ex

132 The secondary prevention measures offered varied across the

133 low implementation of guidelines concerning secondary prevention measures outside of specialized all

134 Ways to better implement secondary prevention measures should be explored in low-

135 This study assessed practice variations in secondary prevention medication prescriptions among coro

136 Exposure was the number of secondary prevention medications (antiplatelets, beta-bl

137 Adherence to key secondary prevention medications (statins, beta-blockers

138 Background Secondary prevention medications are often not prescribe

139 non-STEMI (58% vs 65%), and prescription of secondary prevention medications at discharge.

140 Secondary prevention medicines are unavailable and unaff

141 essful development of new treatments for the secondary prevention of Alzheimer's dementia.

142 Despite the strong evidence for CR in the secondary prevention of ASCVD, it remains vastly underut

143 ase subtilisin/kexin 9 (PCSK9) inhibitors in secondary prevention of ASCVD.

144 designing early intervention strategies for secondary prevention of asthma.

145 remains a major gap in both the primary and secondary prevention of atherosclerotic cardiovascular d

146 rial testing the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular d

147 ensity statin therapy is recommended for the secondary prevention of atherosclerotic cardiovascular d

148 ost-effective compared with current care for secondary prevention of atherosclerotic cardiovascular d

149 n, lisinopril, atenolol, and simvastatin for secondary prevention of atherosclerotic cardiovascular d

150 ng antithrombotic strategies for primary and secondary prevention of atherosclerotic cardiovascular e

151 Statin therapy is indicated in the secondary prevention of atherosclerotic CVD, as well as

152 ition that aspirin is not only effective for secondary prevention of atherothrombosis but also for pr

153 standing paradigm supporting aspirin use for secondary prevention of atherothrombotic events.

154 A2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

155 s P-TIMI 50 [Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

156 The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

157 The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

158 mmation, and differences between primary and secondary prevention of atopic dermatitis to achieve the

159 er, the effect of abstinence from alcohol on secondary prevention of atrial fibrillation is unclear.

160 at least as effective as VKAs in primary and secondary prevention of atrial fibrillation-related isch

161 ancer risk factors and improving primary and secondary prevention of breast cancer.

162 ight provide future treatment options in the secondary prevention of cardioembolic stroke attributabl

163 Data on secondary prevention of cardiovascular disease (CVD) in

164 The benefits of aspirin therapy for the secondary prevention of cardiovascular disease clearly o

165 py, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in

166 ors), commonly prescribed in the primary and secondary prevention of cardiovascular disease, promote

167 ither enalapril or valsartan for primary and secondary prevention of cardiovascular disease.

168 atory drug use except aspirin prescribed for secondary prevention of cardiovascular disease.

169 nd is generally considered effective for the secondary prevention of cardiovascular disease.

170 miological and ET studies in the primary and secondary prevention of cardiovascular diseases, particu

171 s of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events in a UK pr

172 ing opportunities to improve the primary and secondary prevention of cardiovascular events in Ontario

173 al of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were

174 New users of low-dose ASA for secondary prevention of cardiovascular events, aged 50-8

175 indicating that the efficacy of aspirin for secondary prevention of CCS may similarly have changed w

176 ant preventive strategies in the primary and secondary prevention of cerebral hemorrhage include the

177 for a biomarker-driven clinical trial of the secondary prevention of cervical cancer.

178 disease, their effectiveness in primary and secondary prevention of complications is still uncertain

179 For secondary prevention of coronary artery disease (CAD), o

180 structure to study therapies for primary and secondary prevention of COVID-19.

181 e and Pubmed articles related to primary and secondary prevention of CRC and subsequently, a meta-ana

182 225 articles related to primary or secondary prevention of CRC were retrieved.

183 re seems as effective as medical therapy for secondary prevention of cryptogenic ischemic stroke.

184 The primary and secondary prevention of CVD is suboptimal throughout the

185 ials of supplementation of EPA+DHA or ALA in secondary prevention of CVD showed no clear benefit.

186 ntinued investment is crucial in primary and secondary prevention of deaths due to congenital abnorma

187 icoagulant rivaroxaban for the treatment and secondary prevention of deep-vein thrombosis and pulmona

188 an expected at all ages, and ineffective for secondary prevention of diarrhea in children <12 mo of a

189 esting direct-acting oral anticoagulants for secondary prevention of embolic strokes of undetermined

190 ure to that of medical therapy alone for the secondary prevention of embolism in patients with patent

191 ting that this drug should be prescribed for secondary prevention of fetal cardiac disease in anti-SS

192 se cotransporter 2 inhibitors in primary and secondary prevention of HHF.

193 Evidence-based primary and secondary prevention of HIV using opioid agonist therapi

194 ansfusion is the optimal current therapy for secondary prevention of infarcts for children with SCA a

195 Antithrombotic agents are the cornerstone of secondary prevention of ischaemic events but substantial

196 Secondary prevention of ischaemic stroke shares many com

197 XI are potentially tractable new targets for secondary prevention of ischaemic stroke, while factor V

198 Pioglitazone was effective for secondary prevention of ischemic stroke in nondiabetic p

199 Secondary prevention of ischemic stroke includes additio

200 ng the challenges of survivorship, including secondary prevention of long-term morbidity and mortalit

201 rtery disease receive aspirin for primary or secondary prevention of myocardial infarction, stroke, a

202 al suggesting the efficacy of aspirin in the secondary prevention of myocardial infarction.

203 Further evidence that BPs dispensed for secondary prevention of osteoporotic fractures are not a

204 associated with use of BPs in the setting of secondary prevention of osteoporotic fractures.

205 summarizes guideline recommendations for the secondary prevention of paradoxical embolism.

206 this intervention could also be effective in secondary prevention of prolapse and the need for future

207 ar in childhood and adolescence, primary and secondary prevention of psychiatric disorders offers the

208 DI, but there are few data to support use in secondary prevention of recurrent CDI.

209 fore, primary prevention of first stroke and secondary prevention of recurrent stroke are a high prio

210 fectiveness of AIT and its potential role in secondary prevention of respiratory allergy progression.

211 resynchronization therapy in the primary and secondary prevention of SCD.

212 Platelets are common targets for primary and secondary prevention of several conditions.

213 eds (CMBs) in lacunar stroke patients in the Secondary Prevention of Small Subcortical Strokes (SPS3)

214 ecent meta-analyses and randomized trials on secondary prevention of squamous cell carcinoma observed

215 NAVIGATE ESUS (Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemi

216 Urgent improvements to secondary prevention of stroke in China are needed to re

217 e to assist in the diagnosis, treatment, and secondary prevention of stroke in patients in whom an in

218 tween effects of aspirin and dipyridamole in secondary prevention of stroke.

219 Standard therapy for secondary prevention of strokes and silent cerebral infa

220 table cardioverter-defibrillators (ICDs) for secondary prevention of sudden cardiac death were conduc

221 e may therefore be considered for primary or secondary prevention of vascular events with regard to t

222 roxaban is established for the treatment and secondary prevention of venous thromboembolism, but whet

223 atrial fibrillation and in the treatment and secondary prevention of venous thromboembolism.

224 aspirin with anticoagulants for primary and secondary prevention of venous thrombosis.

225 vices could play a major role in primary and secondary prevention of violence against women.

226 dification, and exercise training to improve secondary prevention outcomes in patients with cardiovas

227 us and cardiovascular disease achieved all 5 secondary prevention parameters at baseline, although 71

228 Attainment of 5 secondary prevention parameters-aspirin use, lipid contr

229 mellitus (14 versus 13 years) compared with secondary prevention participants (N=6656; 66%).

230 The rate of appropriate shocks was higher in secondary prevention patients (p < 0.01).

231 revention patients and approximately 400,000 secondary prevention patients.

232 rall therapies and shocks in the subgroup of secondary prevention patients.

233 For secondary prevention, patients at very high risk may be

234 months) or placebo, in addition to standard secondary prevention pharmacotherapy, and were followed

235 r apixaban or rivaroxaban can be used in the secondary prevention phase for appropriate patients.

236 -year risk of recurrent vascular events in a secondary prevention population.

237 n window setting in ICDs in both primary and secondary prevention populations and demonstrates a redu

238 trum of dyslipidemia, event rates similar to secondary prevention populations were observed for patie

239 l cancer in the next 50 years if primary and secondary prevention programmes are not implemented in L

240 Primary and secondary prevention programs for HPV infection and HPV-

241 treatment, and are unlikely to benefit from secondary prevention recommendations to limit disease pr

242 aspirin use were 601 and 391 for primary and secondary prevention, respectively.

243 ome was 10.5% (7.1% and 12.5% in primary and secondary prevention, respectively; P=0.03).

244 an 3.0 years of follow-up, a higher baseline secondary prevention score was associated with improved

245 que shows a potential to improve outcomes of secondary prevention screening for retinoblastoma.

246 g, management of hypertension, diabetes, and secondary prevention) seemed to play an important part i

247 e has been a massive scale-up of primary and secondary prevention services to reduce the population-w

248 herapy, vorapaxar administered for long-term secondary prevention significantly reduced ARC definite

249 rapies and supportive care, but adherence to secondary prevention strategies and long-term care are i

250 testing for CAD, in medical management (both secondary prevention strategies and treatment of stable

251 t and an important opportunity for designing secondary prevention strategies for asthma.

252 of anticoagulant and antiplatelet agents, in secondary prevention strategies for atherosclerosis foll

253 es could be leveraged to promote primary and secondary prevention strategies for these infections to

254 tus for whom closer follow-up and aggressive secondary prevention strategies should be considered.

255 gents and anticoagulants, and greater use of secondary prevention strategies such as statins.

256 Such information will assist in identifying secondary prevention strategies to arrest the atopic mar

257 e is, therefore, a key aspect of primary and secondary prevention strategies.

258 gh risk of melanoma can optimize primary and secondary prevention strategies.

259 rehabilitation (CR) is the only recommended secondary prevention strategy for cardiac patients that

260 MBSR is a safe and well received secondary prevention strategy.

261 Of 3 secondary prevention studies reporting cardiovascular ou

262 Evidence from CVD primary and secondary prevention studies suggested that aspirin ther

263 grade patients were more often implanted for secondary prevention, suffered more often from atrial fi

264 ave been the preferred therapy for long-term secondary prevention, the development of novel oral anti

265 are needed to promote long-term adherence to secondary prevention therapies after revascularization.

266 Rates of medication adherence for secondary prevention therapies ranged from 63.4% to 68.7

267 ave changed with the addition of more modern secondary prevention therapies.

268 oking and lower use of guideline-recommended secondary prevention therapy (both P<0.01).

269 haracteristics, clinical outcomes and use of secondary prevention therapy in patients with ST-segment

270 ich was added to standardised cardiovascular secondary prevention therapy.

271 phylactic HPV vaccination; and prospects for secondary prevention through screening for oral HPV infe

272 infarction and missed opportunities to offer secondary prevention treatment for patients with coronar

273 However, the degree to which secondary prevention treatment goals are achieved in int

274 Clinical trials of secondary prevention treatment in MINOCA patients are la

275 ch 1-mmol/L lower LDL-C level; P = .008) and secondary prevention trials (4.6% lower event rate [95%

276 gy that could improve subject selection into secondary prevention trials and visual assessment in cli

277 VTE as a prospective end point in long-term secondary prevention trials evaluating the risks and ben

278 ome a prerequisite for enrollment in several secondary prevention trials for AD, yet the precise effe

279 s may be important for the designs of future secondary prevention trials for Alzheimer disease.

280 Several large-scale Alzheimer disease (AD) secondary prevention trials have begun to target individ

281 Secondary prevention trials in AD have already begun in

282 ognitive manifestations of AD, and to inform secondary prevention trials in preclinical AD.

283 actors are important to consider in upcoming secondary prevention trials targeting CN individuals at

284 al (CN) individuals is critical for upcoming secondary prevention trials using cognitive outcomes.

285 In CVD primary and secondary prevention trials, 20-year CRC mortality was r

286 may identify participants closest to MCI for secondary prevention trials.

287 ritical for the success of recently launched secondary prevention trials.

288 (AD) are increasingly being targeted for AD secondary prevention trials.

289 ese analyses also suggest the feasibility of secondary prevention trials.

290 in a primary prevention strategy rather than secondary prevention triggered by acute diarrhea.

291 sis In Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2 degrees P) is a simple 9-poi

292 adults with prior cardiovascular disease for secondary prevention was projected to be cost saving in

293 Coverage of primary and secondary preventions was dominated by a strategy of cov

294 r-defibrillator implantation for primary and secondary preventions were retrospectively analyzed.

295 s to prevent the onset of IgE sensitization; secondary prevention, which seeks to interrupt the devel

296 y, and the use of endovascular therapies for secondary prevention, which, so far, have not shown any

297 Among patients with CAD, secondary prevention with a combination of beta-blockers

298 tion, including immunosuppression regimen or secondary prevention with adjuvant chemotherapy.

299 In patients with DM with established CAD, secondary prevention with antiplatelet drugs is an asset

300 Treating all hypertension for primary and secondary prevention would prevent about 800,000 cardiov